SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Minerva Neurosciences, Inc. of a Class Action Lawsuit and a Lead Plaintiff Deadline of February 8, 2021 - NERV

February 03, 2021 6:07 AM EST | Source: Levi & Korsinsky, LLP

New York, New York--(Newsfile Corp. - February 3, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:

To: All persons or entities who purchased or otherwise acquired securities of Minerva Neurosciences, Inc. ("Minerva Neurosciences") (NASDAQ: NERV) between May 15, 2017 and November 30, 2020. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the District of Massachusetts. To get more information go to:

https://www.zlk.com/pslra-1/minerva-neurosciences-inc-loss-submission-form?prid=12641&wire=5

or contact Joseph E. Levi, Esq. either via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. There is no cost or obligation to you.

Cannot view this image? Visit: https://orders.newsfilecorp.com/files/7091/73549_135714_logo.jpg

The complaint alleges that throughout the class period Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) the truth about the feedback received from the FDA concerning the "end-of-Phase 2" meeting; (ii) the Phase 2b study did not use the commercial formulation of roluperidone and was conducted solely outside of the United States; (iii) the failure of the Phase 3 study to meet its primary and key secondary endpoints rendered that study incapable of supporting substantial evidence of effectiveness; (iv) the Company's plan to use the combination of the Phase 2b and Phase 3 studies would be "highly unlikely" to support the submission of an NDA; (v) reliance on these two trials in the submission of an NDA would lead to "substantial review issues" because the trials were inadequate and not well-controlled; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

If you suffered a loss in Minerva Neurosciences you have until February 8, 2021 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.

Levi & Korsinsky is a nationally recognized firm with offices in New York, California, Connecticut, and Washington D.C. The firm's attorneys have extensive expertise and experience representing investors in securities litigation and have recovered hundreds of millions of dollars for aggrieved shareholders. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
55 Broadway, 10th Floor
New York, NY 10006
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/73549

info